Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to obtain safety information on the use of sitagliptin (JANUVIA®) from endocrinologists, diabetologists, internists, and general practitioners.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants treated with sitagliptin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sitagliptin (JANUVIA®) | Drug | Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With an Adverse Event | Up to approximately 28 months | |
| Age of Participants Prescribed Sitagliptin | Up to approximately 28 months | |
| Number of Participants With Concomitant Therapies | Up to approximately 28 months | |
| Number of Participants With Concomitant Conditions | Up to approximately 28 months |
Not provided
Not provided
Inclusion Criteria:
- Must be taking sitagliptin (JANUVIA™) for the treatment of type 2 diabetes
mellitus
- Treating physician must agree to provide information regarding the participants treatment
Not provided
Not provided
Not provided
Not provided
Participants with type 2 diabetes mellitus who are treated with sitagliptin as per the standard of care in a physician's practice
Not provided
This was a postmarketing, safety study of participants with Type 2 diabetes mellitus prescribed sitagliptin phosphate (JUNUVIA®) in clinical practices in the Philippines.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Sitagliptin Phosphate (JANUVIA®) | Participants prescribed Sitagliptin Phosphate (JANUVIA®) in routine clinical practice. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Sitagliptin Phosphate (JANUVIA®) | Participants prescribed Sitagliptin Phosphate (JANUVIA®) in routine clinical practice. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With an Adverse Event | Posted | Number | participants | Up to approximately 28 months |
|
|
Up to approximately 28 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Sitagliptin Phosphate (JANUVIA®) | Participants prescribed Sitagliptin Phosphate (JANUVIA®) in routine clinical practice. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme Corp | 1-800-672-6372 | ClinicalTrialsDisclosure@merck.com |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068900 | Sitagliptin Phosphate |
| ID | Term |
|---|---|
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
| participants |
|
| Sex/Gender, Customized | Number | participants |
|
|
| Primary | Age of Participants Prescribed Sitagliptin | Posted | Mean | Standard Deviation | years | Up to approximately 28 months |
|
|
|
| Primary | Number of Participants With Concomitant Therapies | Posted | Number | participants | Up to approximately 28 months |
|
|
|
| Primary | Number of Participants With Concomitant Conditions | Posted | Number | participants | Up to approximately 28 months |
|
|
|
| 0 |
| 2,974 |
| 0 |
| 2,974 |
Not provided
Not provided
| D004700 | Endocrine System Diseases |
| D011719 |
| Pyrazines |